GALE Stock Analysis: Galenica Sante | SW
Medical Distribution | SW, Switzerland | Market Cap: 4.145m CHF | 12M Return: -2.1% | CH0360674466 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 7.06M
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Galenica AG is a Swiss healthcare company headquartered in Bern, founded in 1927. It operates in two segments: Products & Care, which runs retail pharmacy chains (Amavita, Sun Store, and Coop Vitality) and the specialty pharmacy mediservice, and provides home medication, laboratory and diagnostic services, and consumer health products; and Logistics & IT, which offers pre-wholesale services such as storage, distribution, and debt collection to pharmaceutical manufacturers, along with master data systems, pharmacy management software, and scheduled delivery to pharmacies, drugstores, doctors, hospitals, and care homes.
As a company classified in the Health Care Distributors sub-industry, Galenica sits between pharmaceutical producers and end-points of care, combining B2B logistics with consumer-facing retail pharmacy operations. The Swiss pharmacy sector is subject to cantonal ownership and dispensing rules, which shape how pharmacy chains like Galenicas are structured and expanded.
- Pharmacy network expansion lifts Products & Care revenue
- Logistics & IT margins grow on healthcare digitization demand
- Swiss drug pricing regulation pressures pharmacy margins
| Net Income: 159.2m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.07 > 0.02 and ΔFCF/TA -3.11 > 1.0 |
| NWC/Revenue: 1.70% < 20% (prev 6.07%; Δ -4.38% < -1%) |
| CFO/TA 0.08 > 3% & CFO 251.6m > Net Income 159.2m |
| Net Debt (1.33b) to EBITDA (349.0m): 3.81 < 3 |
| Current Ratio: 1.07 > 1.5 & < 3 |
| Outstanding Shares: last quarter (49.9m) vs 12m ago -0.08% < -2% |
| Gross Margin: 9.86% > 18% (prev 9.74%; Δ 0.12% > 0.5%) |
| Asset Turnover: 133.9% > 50% (prev 131.1%; Δ 2.80% > 0%) |
| Interest Coverage Ratio: 13.89 > 6 (EBIT TTM 204.3m / Interest Expense TTM 14.7m) |
| A: 0.02 (Total Current Assets 1.12b - Total Current Liabilities 1.04b) / Total Assets 3.32b |
| B: 0.43 (Retained Earnings 1.42b / Total Assets 3.32b) |
| C: 0.06 (EBIT TTM 204.3m / Avg Total Assets 3.19b) |
| D: 0.74 (Book Value of Equity 1.41b / Total Liabilities 1.91b) |
| Altman-Z'' = 2.75 = A |
| DSRI: 0.95 (Receivables 629.5m/623.2m, Revenue 4.28b/4.02b) |
| GMI: 0.99 (GM 9.74% / 9.86%) |
| AQI: 1.07 (AQ_t 0.52 / AQ_t-1 0.49) |
| SGI: 1.06 (Revenue 4.28b / 4.02b) |
| TATA: -0.03 (NI 159.2m - CFO 251.6m) / TA 3.32b) |
| Beneish M = -3.00 (Cap -4..+1) = A |
As of September 11, 2026, the stock is trading at CHF 82.70 with a total of 46,100 shares traded. Over the past week, the price has changed by -0.48%, over one month by +0.61%, over three months by -2.59% and over the past year by -2.11%.
Current recommended Stop Loss: 80.10 (which is 3.1% or 2.2 ATR below the current price).
Galenica Sante has no consensus analysts rating.
P/E Trailing = 25.7585
P/E Forward = 20.79
P/S = 0.9674
P/B = 2.9322
Revenue TTM = 4.28b CHF
EBIT TTM = 204.3m CHF
EBITDA TTM = 349.0m CHF
Long Term Debt = 601.5m CHF (from longTermDebt, last fiscal year)
Short Term Debt = 344.1m CHF (from shortTermDebt, last quarter)
Debt = 1.37b CHF (from shortLongTermDebtTotal, last quarter) + Leases 244.0m
Net Debt = 1.33b CHF (calculated: Debt 1.37b - CCE 39.6m)
Enterprise Value = 5.48b CHF (4.15b + Debt 1.37b - CCE 39.6m)
Interest Coverage Ratio = 13.89 (Ebit TTM 204.3m / Interest Expense TTM 14.7m)
EV/FCF = 24.89x (Enterprise Value 5.48b / FCF TTM 220.0m)
FCF Yield = 4.02% (FCF TTM 220.0m / Enterprise Value 5.48b)
FCF Margin = 5.14% (FCF TTM 220.0m / Revenue TTM 4.28b)
Net Margin = 3.72% (Net Income TTM 159.2m / Revenue TTM 4.28b)
Gross Margin = 9.86% ((Revenue TTM 4.28b - Cost of Revenue TTM 3.86b) / Revenue TTM)
Gross Margin QoQ = 9.07% (prev 10.63%)
Tobins Q-Ratio = 1.65 (Enterprise Value 5.48b / Total Assets 3.32b)
Interest Expense / Debt = 1.07% (Interest Expense 14.7m / Debt 1.37b)
Taxrate = 17.18% (33.7m / 196.2m)
NOPAT = 169.2m (EBIT 204.3m * (1 - 17.18%))
Current Ratio = 1.07 (Total Current Assets 1.12b / Total Current Liabilities 1.04b)
Debt / Equity = 0.97 (Debt 1.37b / totalStockholderEquity, last quarter 1.41b)
Debt / EBITDA = 3.81 (Net Debt 1.33b / EBITDA 349.0m)
Debt / FCF = 6.05 (Net Debt 1.33b / FCF TTM 220.0m)
Total Stockholder Equity = 1.47b (last 4 quarters mean from totalStockholderEquity)
RoA = 4.98% (Net Income 159.2m / Total Assets 3.32b)
RoE = 10.82% (Net Income TTM 159.2m / Total Stockholder Equity 1.47b)
RoCE = 9.86% (EBIT 204.3m / Capital Employed (Equity 1.47b + L.T.Debt 601.5m))
RoIC = 6.54% (NOPAT 169.2m / Invested Capital 2.59b)
WACC = 3.73% (E(4.15b)/V(5.52b) * Re(4.67%) + D(1.37b)/V(5.52b) * Rd(1.07%) * (1-Tc(0.17)))
Discount Rate = 4.67% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 53.35 | Cagr: 0.18%
[DCF] Terminal Value 73.10% ; FCFF base≈251.3m ; Y1≈220.4m ; Y5≈178.0m
[DCF] Fair Price = 30.64 (EV 2.86b - Net Debt 1.33b = Equity 1.53b / Shares 49.8m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: N/A | # QB: 0
Revenue Correlation: 99.53 | Revenue CAGR: 5.50% | SUE: N/A | # QB: 0
EPS current Year (2026-12-31): EPS=3.85 | Chg30d=-3.76% | Revisions=-17% | GrowthEPS=+2.4% | GrowthRev=+6.1%
EPS next Year (2027-12-31): EPS=4.25 | Chg30d=-0.52% | Revisions=+0% | GrowthEPS=+10.4% | GrowthRev=+3.2%
[Analyst] Revisions Ratio: -12% (up=2, down=3)